TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00447408

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard hemodialysis dietary instruction
Description: Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus PDA-based self-monitoring of diet
Description: Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
Study: NCT00492011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
Study: NCT03513419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AMOR Method
Description: The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
Study: NCT00846365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil-hydrochlorothiazide
Description: Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Study: NCT04221529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg i.v. on day 1 of each cycle
Study: NCT01576848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein + carbohydrate
Description: subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein + carbohydrate
Description: subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).
Study: NCT02072200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra®
Description: Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
Study: NCT03501251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 8mg
Description: Participants will receive the tablet with clean water and a package of biscuits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 8 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 16 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study: NCT06727656

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The combined effect of placebo supplementation and normoxia training on both performance and health at sea-level and altitude conditions.
Study: NCT03501251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 16 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 24 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 24 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the tablet with clean water and a package of biscuits.
Study: NCT00392106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propafenone
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flecainide
Description: Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dofetilide
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sotolol
Description: Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation
Description: Electrical isolation of pulmonary vein with high-intensity focused ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
Study: NCT02087098

Intervention type: DRUG
Intervention: Solifenacin
Description: Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
Study: NCT03500978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer CBT Intervention
Description: Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
Study: NCT00721799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluorothymidine PET scan
Description: 18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
Study: NCT01548365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion therapy nursing expert service
Description: The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device.
Study: NCT00003723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
Study: NCT02394756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Soft Contact lens
Description: Replacement schedule every 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Soft Contact lens
Description: Replacement schedule every 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marketed Soft Contact lens
Description: Replacement schedule every 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIR OPTIX® AQUA
Description: Replacement schedule every 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIR OPTIX® AQUA
Description: Replacement schedule every 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIR OPTIX® AQUA
Description: Replacement schedule every 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity®
Description: Replacement schedule every 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity®
Description: Replacement schedule every 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity®
Description: Replacement schedule every 4 weeks
Study: NCT01399307

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liposuction
Description: Elective Liposuction
Study: NCT00398229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: s.c. human chorionic gonadotropin (Ovitrelle)
Description: S.C. Ovitrelle 250 mcg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: s.c. human chorionic gonadotropin (Ovitrelle)
Description: S.C. Ovitrelle 250 mcg once
Study: NCT03025373

Intervention type: OTHER
Intervention: Visuo-acoustic stimulation
Description: Controlled visual and acoustic stimulation in a virtual reality setting

Intervention type: OTHER
Intervention: Visuo-acoustic stimulation
Description: Controlled visual and acoustic stimulation in a virtual reality setting
Study: NCT00676949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1
Description: 1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
Study: NCT00001305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: Patients receive a subcutaneous injection.
Study: NCT01220284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin in combo with vinorelbine
Description: * Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks.
Study: NCT04079504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation of indirect hernia sac
Description: Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-ligation of Indirect Inguinal hernia sac
Description: the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
Study: NCT02811770

Intervention type: OTHER
Intervention: kidney biopsy
Study: NCT04584788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3 Regional Oximeter
Description: Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
Study: NCT04386447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients.
Study: NCT00834041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 3.125 mini-tablets
Description: Oral mini-tablets (3.125 mg) of aliskiren once each morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 3.125 mini-tablets
Description: Oral mini-tablets (3.125 mg) of aliskiren once each morning
Study: NCT03918317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirXpanders AeroFormtissue expander
Description: The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
Study: NCT02632617

Intervention type: OTHER
Intervention: Computed tomographic angiography
Description: Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
Study: NCT03826251

Intervention type: PROCEDURE
Intervention: Nasogastric tube removal
Description: Nasogastric tube was removed immediately after surgery
Study: NCT02756312

Intervention type: OTHER
Group type: OTHER
Intervention: IV Anesthesia
Description: The patients will receive intravenous anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: IH anesthesia
Description: The patients will receive inhalation anesthesia
Study: NCT02490709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision
Description: Local excision for rectal cancer with good response
Study: NCT01110265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo training
Study: NCT03231475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH1188-11
Description: qd.po
Study: NCT02724683

Intervention type: DEVICE
Intervention: Ascites drainage with vascular catheter.
Description: In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.

Intervention type: BEHAVIORAL
Intervention: Interview.
Description: Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.

Intervention type: BEHAVIORAL
Intervention: Quality of life.
Description: Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.

Intervention type: DEVICE
Intervention: Quality of procedure.
Description: Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.

Intervention type: OTHER
Intervention: Nutritional status
Description: Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
Study: NCT00662025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily, continuous dosing
Study: NCT04560881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (Vero cell)
Description: Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
Study: NCT04309331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Motion
Description: Amino acid based protein substitute
Study: NCT03908411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paratracheal pressure
Description: Paratracheal pressure is applied by 30N force with the ultrasound transducer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sellick's maneuver
Description: Conventional Sellick's maneuver is applied by 30N force
Study: NCT01740206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine and/or methylphenidate
Description: Patients who took their stimulant medication the day of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold stimulant medication
Description: Patients who held their stimulant medication the day of surgery.
Study: NCT05074901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital behavioral intervention
Description: interaction with a conversational agent to implement physical and cognitive programs
Study: NCT00948545

Intervention type: OTHER
Intervention: Observational study - there is no intervention
Description: Observational study - there is no intervention
Study: NCT00322322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine
Study: NCT02117518

Intervention type: OTHER
Intervention: blood drawing
Study: NCT03621956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped within 30 seconds of delivery.
Study: NCT01782339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Chemotherapy
Description: 4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle.
Study: NCT02431013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg on Day 1 \& Day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 20 mg on Day 1 \& Day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
Study: NCT03615963

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography and coronary angiography
Description: transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography and coronary angiography
Description: transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
Study: NCT03159403

Intervention type: DRUG
Intervention: Oritavancin
Description: This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Study: NCT03256578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Life Box Respiratory Function Monitor
Description: The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
Study: NCT00745888

Intervention type: OTHER
Intervention: Chemiluminescence Analyzer
Description: measure reactive oxygen species